ML239 is a potent and selective breast cancer stem cell inhibitor with IC50 ~1.16 μM. It displayed greater than 23-fold selective inhibition of the breast CSC-like cell line (HMLE_sh_Ecad) over the isogenic control cell line (HMLE_sh_GFP). It did not significantly inhibit tumorsphere formation in the breast cancer cell line SUM159, which is a mixture of CSCs and differentiated cells. ML239 is also cytotoxic towards MDA-MB-231 breast cancer cells.
CAS Number: 1378872-36-6
Molecular Weight: 346.60
Chemical Name: (E)-N'-((1H-pyrrol-2-yl)methylene)-2-(2,4,6-trichlorophenoxy)acetohydrazide
Appearance: Solid Power.
Purity: ≥98% (or refer to the Certificate of Analysis)
Solubility: DMSO up to 100 mM
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life: ≥360 days if stored properly.
Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.
Drug Formulation: To be determined.
HS Tariff Code: 382200
How to use
ML239 was used at 10 µM final concentration in vitro and in cellular assays.
- Carmody LC, et al. Phenotypic high-throughput screening elucidates target pathway in breast cancer stem cell-like cells. (2012) J Biomol Screen. 17(9):1204-10.
- Germain AR, et al. Identification of a selective small molecule inhibitor of breast cancer stem cells. (2012) Bioorg Med Chem Lett. 22(10):3571-4.
Products are for research use only. Not for human use.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.